|1.||Gulley, James L: 21 articles (01/2015 - 07/2007)|
|2.||Madan, Ravi A: 17 articles (01/2015 - 12/2008)|
|3.||Jaffee, Elizabeth M: 14 articles (01/2015 - 07/2003)|
|4.||Old, Lloyd J: 14 articles (04/2012 - 04/2002)|
|5.||Schlom, Jeffrey: 13 articles (01/2014 - 11/2004)|
|6.||Koido, Shigeo: 12 articles (10/2015 - 02/2003)|
|7.||Morse, Michael A: 11 articles (11/2012 - 02/2005)|
|8.||Itoh, Kyogo: 10 articles (01/2014 - 06/2003)|
|9.||Gong, Jianlin: 10 articles (12/2013 - 02/2003)|
|10.||Emens, Leisha A: 9 articles (05/2015 - 07/2003)|
11/01/2015 - "Peptide cancer vaccines may be most effective in patients with a lower disease burden, when cancer tolerance is minimized. "
04/01/2009 - "The high efficacy of the two available cervical cancer vaccines and their proven ability to reduce the incidence of cervical cancer precursor lesions offer hope that the vaccine will have enormous worldwide impact and may dramatically reduce the cervical cancer burden. "
06/15/2008 - "Most of the current tumor vaccines successfully elicit strong protection against tumor but offer little therapeutic effect against existing tumors, highlighting the need for a more effective vaccine strategy. "
04/01/2006 - "However, experimental cancer vaccines, although in some patients result in elimination of large tumor burdens, have a low frequency of long-term cancer remission in most patients, ca. <5%. "
10/01/2003 - "As prophylactic tumor vaccines, the combined use of gene-modified BM1/sFlt3L+GM-CSF+IL-12 x CD80 was most effective, providing 100% protection against subsequent parental BM1 tumor challenge. "
|2.||Melanoma (Melanoma, Malignant)
08/01/2003 - "To test whether homeostasis-driven T cell proliferation in reconstituted lymphodepleted hosts would improve the therapeutic efficacy of tumor vaccines, normal mice and reconstituted lymphopenic mice (RLM; C57BL/6 mice rendered lymphopenic with sublethal total-body irradiation and reconstituted with naive splenocytes) were used in the vaccination and challenge experiments with weakly immunogenic F10 melanoma cells. "
10/01/2013 - "Since the publication of the first clinical trial in melanoma patients in 1995, therapeutic dendritic cell cancer vaccines have been extensively studied in numerous phase I and II trials. "
04/01/2003 - "At present, there are no FDA-approved cancer vaccines for malignant melanoma, and the results of ongoing randomized phase III clinical trials are greatly anticipated."
02/15/2014 - "Collectively, our findings support the use of PD-1 and Tim-3 blockades with cancer vaccines to stimulate potent antitumor T-cell responses and increase the likelihood of clinical responses in patients with advanced melanoma."
02/15/2014 - "To investigate this discrepancy, we evaluated the character of vaccine-induced CD8(+) T cells with regard to the inhibitory T-cell coreceptors PD-1 and Tim-3 in patients with metastatic melanoma who were administered tumor vaccines. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2010 - "Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression."
03/01/2013 - "Cancer vaccines have been utilized as a therapeutic modality to treat prostate cancer in clinical studies for several decades. "
06/01/2011 - "From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer."
12/01/2010 - "Additional clinical trials will further our understanding of the role of therapeutic cancer vaccines and add new agents to the armamentarium of therapy for patients with prostate cancer."
07/01/1999 - "This study suggests that DC-based cancer vaccines in the future may provide an additional therapy for advanced prostate cancer."
|4.||Breast Neoplasms (Breast Cancer)
11/01/2015 - "Our experience with three peptide cancer vaccines, E75, GP2 and AE37, in clinically disease-free breast cancer patients provides encouraging results that this method may be effective. "
02/01/2004 - "In this study, we used syngeneic metastatic (4TO7) and non-metastatic (64pT) breast tumor models to obtain valuable information on the potential usefulness of MAGE-encoding cancer vaccines in metastatic and non-metastatic breast cancer at old age. "
11/01/2015 - "Adjuvant HER2/neu peptide cancer vaccines in breast cancer."
05/01/2009 - "Tumor vaccines for breast cancer."
12/01/2007 - "Immunology and breast cancer: therapeutic cancer vaccines."
12/01/2014 - "This review is based on a search of relevant literature for data presented over the past 5 years from clinical trials of cancer vaccines in prostate, bladder and renal carcinomas. "
01/01/2004 - "The obtained data indicate that the IL-12-transduced murine colon carcinoma cells could be used both as a model tumour for the study of mechanisms of anticancer immunity and/or as an adjuvant to cancer vaccines."
10/01/2010 - "Cancer vaccines may have applications in the therapy and prevention of mammary carcinoma. "
08/01/2002 - "Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines."
02/01/2008 - "HLA class I loss is a significant mechanism of immune evasion by cervical carcinoma, interfering with the development of immunotherapies and cancer vaccines. "
|7.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|10.||DNA (Deoxyribonucleic Acid)
|2.||Drug Therapy (Chemotherapy)